REMEGEN announced its performance for the first three quarters, with a net loss attributable to the parent company of approximately 551 million yuan, narrowing by 48.6% year-on-year
I'm PortAI, I can summarize articles.
榮昌生物公佈 2025 年前三季度業績，營業收入約 17.2 億元，同比增長 42.27%；歸母淨虧損約 5.51 億元，同比收窄 48.6%。基本每股虧損 1.01 元。淨虧損減少主要由於產品銷售收入增加、研發支出下降及與美國 Vor Bio 公司簽訂許可協議，導致海外臨牀費用減少。
智通財經 APP 訊，榮昌生物 (09995) 公佈 2025 年前三季度業績，營業收入約 17.2 億元，同比增長 42.27%;歸屬於上市公司股東的淨虧損約 5.51 億元，同比收窄 48.6%;基本每股虧損 1.01 元。
公告稱，淨虧損減少主要是由於產品銷售收入大幅度增加，另公司研發管線優化，各項研發支出下降，加之公司與美國 Vor Bio 公司訂立許可協議約定將具有自主知識產權的泰它西普有償許可給美國 VorBio 公司，美國 Vor Bio 公司將獲得在除大中華區以外的全球範圍內開發和商業化的獨家權利，由此導致泰它西普海外臨牀費用減少，進而導致本年虧損大幅下降。
Source: 智通財經 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments